[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.177.17. Please contact the publisher to request reinstatement.
Views 371
Citations 0
Comment & Response
March 2017

Where Is the Geriatrician?

Author Affiliations
  • 1Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
  • 2Department of Geriatrics, Neurosciences and Orthopedics, Catholic University of the Sacred Heart School of Medicine, Rome, Italy
JAMA Intern Med. 2017;177(3):441-442. doi:10.1001/jamainternmed.2016.8853

To the Editor We have read with great interest the article by Munson and colleagues1 in a recent issue of JAMA Internal Medicine exploring the use of prescription drugs associated with fracture risk in patients with fragility fractures. At the time of fracture, about three-quarters of patients were receiving at least 1 drug associated with increased fracture risk. The prescription pattern did not substantially change following the fracture event.

×